Retraction to: Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo (Int. J. Cancer, (2011), 128, (1240–1250), 10.1002/ijc.25658);Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1240-1250

  Banerjee, Sanjeev ^a   Kong, Dejuan ^a   Azmi, Asfar S ^a   Wang, Zhiwei ^a   Ahmad, Aamir ^a   Sethi, Seema ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemosensitization; gensitein; NF B; oxaliplatin; pancreatic cancer

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CASPASE 9; GELATINASE B; GEMCITABINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; KI 67 ANTIGEN; OXALIPLATIN; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CHEMOSENSITIZATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 78650743255     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30271     Document Type: Erratum

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Sarkar FH, Li Y,. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 2009; 35: 597-607.
3. Amin AR, Kucuk O, Khuri FR, Shin DM,. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009; 27: 2712-25.
4. Dennis T, Fanous M, Mousa S,. Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer 2009; 61: 587-97.
5. Sarkar FH, Li Y,. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002; 21: 265-80.
6. Sarkar FH, Li Y,. Soy isoflavones and cancer prevention. Cancer Invest 2003; 21: 744-57.
7. Ducreux M, Boige V, Malka D,. Treatment of advanced pancreatic cancer. Semin Oncol 2007; 34 (2 Suppl 1): S25-S30.
8. O'Reilly EM, bou-Alfa GK,. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007; 34: 347-53.
9. Xiong HQ, Carr K, Abbruzzese JL,. Cytotoxic chemotherapy for pancreatic cancer: advances to date and future directions. Drugs 2006; 66: 1059-72.
10. Saif MW, Kim R,. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother 2007; 8: 2719-27.
11. Banerjee S, Li Y, Wang Z, Sarkar FH,. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008; 269: 226-42.
12. Ren MQ, Kuhn G, Wegner J, Chen J,. Isoflavones, substances with multi-biological and clinical properties. Eur J Nutr 2001; 40: 135-46.
13. Roginsky AB, Ujiki MB, Ding XZ, Adrian TE,. On the potential use of flavonoids in the treatment and prevention of pancreatic cancer. In Vivo 2005; 19: 61-7.
14. Imai Y, Tsukahara S, Asada S, Sugimoto Y,. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004; 64: 4346-52.
15. Limtrakul P, Khantamat O, Pintha K,. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005; 17: 86-95.
16. Liao CH, Pan SL, Guh JH, Teng CM,. Genistein inversely affects tubulin-binding agent-induced apoptosis in human breast cancer cells. Biochem Pharmacol 2004; 67: 2031-8.
17. Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH,. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett 2009; 278: 201-9.
18. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH,. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-κB. Cancer Res 2006; 66: 10553-9.
19. Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH,. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor κ B in nonsmall cell lung cancer cell lines. Cancer 2009; 115: 2165-76.
20. Hwang JT, Ha J, Park OJ,. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005; 332: 433-40.
21. Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, Kim WJ, Choi YH,. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 2009; 20: 713-22.
22. Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H,. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Cancer Lett 2010; 292: 54-63.
23. Roy CS, Karmakar S, Banik NL, Ray SK,. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. Invest New Drugs [Epub ahead of print].
24. Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, Kim W, Davaatseren M, Hwang JT, Kim HJ, Kim MS, Kwon DY, et al. Genistein protects the kidney from cisplatin-induced injury. Kidney Int 2008; 74: 1538-47.
25. Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL, Chiao PJ,. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin Cancer Res 2009; 15: 6367-77.
26. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH,. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064-72.
27. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH,. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007; 120: 906-17. (Pubitemid 46175414)
28. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM,. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 2009; 69: 5575-83.
29. Banerjee S, Wang Z, Kong D, Sarkar FH,. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009; 69: 5592-600.
30. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH,. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064-72.
31. Androulakis N, Syrigos K, Polyzos A, Aravantinos G, Stathopoulos GP, Ziras N, Mallas K, Vamvakas L, Georgoulis V,. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 2005; 23: 9-12.
32. Custodio A, Puente J, Sastre J, az-Rubio E,. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev 2009; 35: 676-84.
33. Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH,. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κB in BxPC-3 pancreatic cancer cell line. Pancreas 2004; 28: e90-e95.
34. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM,. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105: 735-46.
35. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD,. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008; 14: 8143-51.
36. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H,. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-51.
37. Sebens S, Arlt A, Schafer H,. NF-κB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res 2008; 177: 151-64.
38. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S, Krissansen GW, Sun X,. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2010; 291: 90-8.
39. Sato T, Odagiri H, Ikenaga SK, Maruyama M, Sasaki M,. Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor. Cancer Sci 2003; 94: 467-72.
40. Liu WS, Yan HJ, Qin RY, Tian R, Wang M, Jiang JX, Shen M, Shi CJ,. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 2009; 54: 89-96.
41. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW,. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010; 8: 24-34.